Amicus Therapeutics, Inc lost $0.09 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Amicus Therapeutics, Inc has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.09
YoYn/m
5Y CAGRn/m
10Y CAGRn/m
Source SEC Filings (10-K/10-Q)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
FOLD EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Amicus Therapeutics, Inc lost $0.09 per diluted share in fiscal year 2025.
Amicus Therapeutics, Inc (FOLD) reported a loss of $0.18 per diluted share in fiscal year 2024 and a loss of $0.09 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 15 fiscal years this page covers, Amicus Therapeutics, Inc (FOLD) diluted earnings per share went from -$1.28 in fiscal year 2011 to -$0.09 in fiscal year 2025.
Amicus Therapeutics, Inc (FOLD) reported $0.00 in diluted earnings per share in Q4 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Amicus Therapeutics, Inc (FOLD) reported on that line in every period on record.
